| [1] Friess W. Collagen-biomaterial for drug delivery [J].European Journal of Pharmaceutics and Biopharm aceutics, 1998, 45 (2): 113-136.[2] 蒋挺大，张春萍: 胶原与胶原蛋白[M].北京化学工业出版社; 2006.[3] James M P, Marcella C, Caterina M, et al. Identification, characterization and expression analysis of a new fibrillar collagen gene, COL27A1 [J]. Matrix Biology, 2003, 22 (1): 3-14.[4] Patrizia Sabatelli, Francesca Gualand, Sudheer Kumar Gara, et al. Expression of collagen VI α5 and α6 chains in human muscle and in Duchenne muscular dystrophy-related muscle fibrosis[J]. Matrix Biology 31 (2012) 187–196.[5] Engel J, Furthmayr H, Odermatt E, von der Mark H, Aumailley M, Fleischmajer R, Timpl R. Structure and macromolecular organization of type VI collagen.[J].Ann N Y Acad Sci 1985;460:25–37.[6] Camacho Vanegas O, Bertini E, Zhang RZ et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI.[J].Proc Natl Acad Sci USA 2001; 98: 7516–7521.[7] J?bsis, G.J., Keizers, H., Vreijling, J.P., de Visser, M., Speer, M.C., Wolterman, R.A., Baas, F., Bolhuis, P.A., 1996. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures.[J].Nat. Genet. 14, 113–115.[8] Merlini, L., Martoni, E., Sabatelli, P., Squarzoni, S., Bovolenta, M., Messina, S., Mercuri, E.,Franchella, A., Ferlini, A., Bonaldo, P., 2008. Autosomal recessive myosclerosis myopathy is a collagen VI disorder.[J].Neurology 71, 1245–1253.[9] David Olsen, Chunlin Yang, Michael Bodo, et al.. Recombinant collagen and gelatin for drug delivery [J]. Advanced Drug Delivery Reviews 55 (2003) 1547– 1567[10] L. Cooperman, D. Michaeli, The immunogenicity of injectable collagen: I. A 1-year prospective study.[J].Am. Acad. Dermatol. 10 (1984) 638– 646[11] Cheryl Wong Po Foo, David L. Kaplan. G enetic engineering of fibrous proteins: spider dragline silk and collagen.[J] Advanced Drug Delivery Reviews 54 (2002) 1131–1143[12] Bruns, R.R., 1984. Beaded filaments and long-spacing fibrils: relation to type VI collagen[J].Ultrastruct. Res. 89, 136–145.[13] J.M. Cregg, J. Lin-Cereghino, J. Shi, D.R. Higgins, Recombinant protein expression in Pichia pastoris.[J].Mol. Biotechnol. 16 (2000)，23–52.[14] J.M. Cregg, T.S. Vedvick, W.C. Easchke, Recent advances in the expression of foreign genes in Pichia pastoris.[J].Bio/Technology 11 (1993) 905–910.[15] Xianzong Shi, Tammy Karkut, Mahmood Chamankhah, et al. Optimal conditions for the expression of a single-chain antibody (scFv) gene in Pichia pastoris [J]. Protein Expression and Purification 28 (2003) 321–330.[16] ?elik E, ?al?k P, Production of recombinant proteins by yeast cells.[J].Biotechnol Adv (2011)[17] Gabriel Potvin, Ayla Ahmad, Zisheng Zhang. Bioprocess engineering aspects of heterologous protein production in Pichiapastoris: A review[J]. Biochemical Engineering Journal 64 (2012) 91–105[18] K. Sreekrishna, R.B. Brankamp, K.E. Kropp, D.T. Blankenship, J.T. Tsay, P.L.Smith, J.D. Wierschke, A. Subramaniam, L.A. Birkenberger, Strategies for optimal synthesis and secretion of heterologous proteins in the methylotrophic yeast Pichia pastoris[J]. Gene 190 (1997) 55–62.[19] 吴铭. 重组人胶原蛋白肽在大肠杆菌中的高效表达及其生物活性研究[D]. 吉林农业大学 2011[20] 高力虎，重复序列类人胶原蛋白表达载体的构建及在毕赤酵母中的分泌表达[D]. 北京:中国优秀硕士学位论文全文数据库，2007[21] Vuorela A, Myllyharju J, Nissi R, et al. Assembly of human prolyl 4-hydroxylase and typeⅢ collagen in the yeast Pichia Pastoris: formation of a stable enzyme tetramer requires coexpression with collagen and assembly of a stable collagen requires coexpression with prolyl 4-hydroxylase[J].The EMBO Joumal,1997,16(22):6702~6712 |
